Cover Image

Osimertinib-induced Cardiac Dysfunction in EGFR-Mutated Lung Cancer: A Case Series of Five Patients

Maria Lucia Reale, Matteo Bianco, Fabrizio Tabbò, Annapaola Mariniello, Paola Destefanis, Alessia Luciano, Paolo Bironzo, Simona Carnio, Enrica Cappelletto, Roberto Pozzi, Silvia Novello

Abstract


Introduction: The gold standard treatment for Epidermal Growth Factor Receptor (EGFR) positive Non-Small Cell Lung Cancer (NSCLC)patients is represented byosimertinib, an irreversible third-generation EGFR inhibitor that has been providingimportant outcomes’ improvementscompared to chemotherapy and other target therapies; either upfront or as second line therapy, in case of  EGFR T790M detection after previous tyrosine kinase inhibitors (TKI).Osimertinib is generally well tolerated. Most common side effects are diarrhea, rash, paronychia, dry skin and alsochanges in QT interval.

Presentation of case series: Here we report five cases of left ventricular dysfunction duringosimertinib treatment, observed between January 2017 and August 2018. The five patients, with a general low cardiovascular risk profile, required a dose modification/discontinuation of the TKI therapy and a specific cardio-protective treatment, normally with a recovery of the systolic function.

Conclusion: Both American and European compound labels highlight warnings of cardiomyopathy and changes in cardiac contractility during osimertinib treatment, recommending cardiac monitoring and dose adjustment in patients with cardiac risk factors. In spite of this, a standardized echocardiographic follow-up in the entire population is still not available and recommendations about the use of tissue Doppler echocardiography with more sophisticated indices are missing. With the expanding use of osimertinib we need better strategies to prevent or mitigate cardiovascular damage from cancer therapy in a larger multidisciplinary approach in which every issue is carefully evaluated.


Keywords


EGFR, lung cancer, osimertinib, cardiac toxicity, echocardiography

Full Text:

PDF

References


Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004, 304:1497-1500

Mitsudomi T, Morita S, Yatabe Y, et al.West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non–small cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11:121-128

Rosell R, Carcereny E, Gervais R, et al; Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation–positive non–small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012, 13:239-246

Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J ClinOncol. 2013, 31:3327-3334

Mok TS, Cheng Y, Zhou X, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J ClinOncol. 2018, 36(22):2244-2250.

Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014, 20:2249-2256.

Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016, 17(12):1643-1652.

Mok TS, Wu YL, Ahn MJ, et al.AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017, 376:629-640.

Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018, 378:113-125

Watanabe H, Ichihara E, Kano H, et al. Congestive Heart Failure DuringOsimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). InternMed. 2017, 56(16):2195-2197

Oyakawa T, Nakashima K, Naito T. Cardiac Dysfunction Caused by Osimertinib. J ThoracOncol. 2017, 12(10):e159-e160

AstraZeneca. Tagrisso™ (osimertinib) tablets, for oral use: US prescribing information. 2017. http://www.fda.gov/. Accessed 24 March 2018.

Reichelt ME, O'Brien S, Thomas WG, et al. Transactivation of the epidermal growth factor receptor in responses to myocardial stress and cardioprotection. Int J Biochem Cell Biol. 2017, 83:97-110

Ben Aissa A, Mach N. Is lung cancer in women different?. Rev Med Suisse. 2012, 8(342):1108-1111.

Honda K, Takeshita K, Murotani K, et al. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer. Breast Cancer. 2016, 24: 312-318

Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J ClinOncol. 2005, 23(13):2900-2902


Refbacks

  • There are currently no refbacks.


AJCC-REP (ISSN 2572-5742)Copyright © 2012-2020. All rights reserved. Published by Ivy Union Publishing, 3204 Valley Rush Dr, Apex, North Carolina 27502, United States